Efficacy and safety of perioperative application of ketamine on postoperative depression: A meta-analysis of randomized controlled studies
Jie Guo, Di Qiu, Han-Wen Gu, Xing-Ming Wang, K. Hashimoto, Guang-Fen Zhang, Jian-Jun Yang
Molecular Psychiatry January 20, 2023 DOI: 10.1038/s41380-023-01945-z via Semantic Scholar
Summary
Perioperative intravenous ketamine reduces postoperative depression scores and pain scores on the first day after surgery but increases the risk of adverse effects including nausea, vomiting, headache, hallucination, and dizziness. The analysis of 15 randomized controlled trials with 1697 patients receiving ketamine and 1462 controls showed a reduction in depression scores on postoperative days 1, 3, and 7 and over the long term. Pain scores were lower only on the first postoperative day. The authors conclude that ketamine's benefits for postoperative depression and pain must be weighed against its increased adverse effects.
Study at a glance
| Characteristics | Meta-analysis Randomized Peer reviewed |
|---|---|
| Sample size | 3,159 |
| Population | Patients undergoing surgery |
| Keywords | Medicine |
| Citations | 46 |
| Key finding | Perioperative ketamine reduces postoperative depression scores and pain scores on day one but increases the risk of nausea, vomiting, headache, hallucination, and dizziness. |
Abstract
Ketamine, a commonly used general anesthetic, can produce rapid and sustained antidepressant effect. However, the efficacy and safety of the perioperative application of ketamine on postoperative depression remains uncertain. We performed a meta-analysis to determine the effect of perioperative intravenous administration of ketamine on postoperative depression. Randomized controlled trials comparing ketamine with placebo in patients were included. Primary outcome was postoperative depression scores. Secondary outcomes included postoperative visual analog scale (VAS) scores for pain and adverse effects associated with ketamine. Fifteen studies with 1697 patients receiving ketamine and 1462 controls were enrolled. Compared with the controls, the ketamine group showed a reduction in postoperative depression scores, by a standardized mean difference (SMD) of −0.97, 95% confidence interval [CI, −1.27, −0.66], P < 0.001, I^2 = 72% on postoperative day (POD) 1; SMD−0.65, 95% CI [−1.12, −0.17], P < 0.001, I^2 = 94% on POD 3; SMD−0.30, 95% CI [−0.45, −0.14], P < 0.001, I^2 = 0% on P OD 7; and SMD−0.25, 95% CI [−0.38, −0.11], P < 0.001, I^2 = 59% over the long term. Ketamine reduced VAS pain scores on POD 1 (SMD−0.93, 95% CI [−1.58, −0.29], P = 0.005, I^2 = 97%), but no significant difference was found between the two groups on PODs 3 and 7 or over the long term. However, ketamine administration distinctly increased the risk of adverse effects, including nausea and vomiting (risk ratio [RR] 1.40, 95% CI [1.12, 1.75], P = 0.003, I^2 = 30%), headache (RR 2.47, 95% CI [1.41, 4.32], P = 0.002, I^2 = 19%), hallucination (RR 15.35, 95% CI [6.^24, 37.34], P < 0.001, I^2 = 89%), and dizziness (RR 3.48, 95% CI [2.68, 4.50], P < 0.001, I^2 = 89%) compared with the controls. In conclusion, perioperative application of ketamine reduces postoperative depression and pain scores with increased risk of adverse effects.